CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk

The purpose of this study is to evaluate the safety and feasibility of a treatment holiday strategy directed by CD70-targeted immuno-PET/CT in patients with metastatic clear cell renal cell carcinoma (mccRCC). Specifically, the study aims to assess whether patients who achieve both anatomical disease control and metabolic response after 12 months of first-line PD-1/PD-L1 ICI + VEGFR-TKI combination therapy can safely pause their treatment, improve quality of life without compromising therapeutic efficacy.

Trial Details

NCT ID
NCT07615348
Phase
PHASE2
Sponsor
Jinling Hospital, China
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • PD-1/PD-L1 ICI + VEGFR-TKI
  • Treatment pause
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Wuxi, Jiangsu, China|31.56887,120.28857

Key Eligibility Criteria

  • STEP0: At Treatment Initiation
  • Male or female subjects aged ≥ 18 years
  • Locally advanced (not amenable to curative surgery or radiation therapy) or metastatic RCC (American Joint Committee on Cancer \[AJCC\] Stage IV)
  • Histologically or cytologically confirmed advanced RCC with predominantly clear-cell subtype

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →